Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation

Clinical trial NCT02513186 · COMPLETED

Trial details

NCT number: NCT02513186
Sponsor: Sanofi
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Plasma Cell Myeloma

Start date: 2015-09-30
Primary completion: 2022-01-28
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.